Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy

Stress Disorders, Post-Traumatic Clinical Trial

Official title:

Sustaining Remission From Posttraumatic Stress Disorder (PTSD) Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05274230
• Other study ID #: AN006
• Secondary ID: 20214600
• Status: Recruiting
• Phase: N/A
• Start date: December 8, 2021
• Est. completion date: December 31, 2025

Study information

• Verified date: January 2023
• Source: Apollo Neuroscience, Inc.
• Contact: Nicole Grinsell, MS
• Phone: 8559220057
• Email: nicole[@]apolloneuro.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to examine a wearable device called Apollo that emits gentle vibrations found to benefit mood, energy, and focus. We want to understand how it affects outcomes related to MDMA-assisted psychotherapy for PTSD including depression, anxiety and emotion regulation. This study will test whether regular use of the Apollo wearable improves rates of sustained symptom remission in PTSD following MDMA-assisted psychotherapy over the course of two years

Description:

The study examines the effect of the Apollo wearable on its users after undergoing MDMA-assisted psychotherapy. There will be no study specific modification to the MDMA-assisted psychotherapy that participants receive. All study participants will have previously consented to MAPS MDMA-assisted psychotherapy for PTSD clinical trial before enrolling in this protocol. Once they have been identified as people who have been consented to the MAPS trial regardless of this research, they will be approached about the study, and screened/consented/enrolled accordingly. Participants will receive the Apollo wearable device via mail upon consenting to participate in this study. They will be provided an instruction manual with guidelines on how to best use the device and will be asked to continue to use the Apollo device in their everyday life following MDMA-assisted psychotherapy. Participants in the study will be asked to complete monthly online questionnaires for the duration of the two year study. Please note: this study is not affiliated with the MAPS organization who is running the MDMA-assisted psychotherapy research study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 or over
• Completion of the MAPS MDMA-Assisted Psychotherapy for PTSD clinical trial (treatment cohort)
• completion of the MAPS MDMA-Assisted Psychotherapy for PTSD clinical trial (placebo cohort)
• enrolled in the MAPS MDMA-Assisted Psychotherapy for PTSD clinical trial, but dropped out

Exclusion Criteria:

• Unable to give adequate informed consent
• Have any current problem which, in the opinion of the investigator might interfere with participation
• Are unable to complete questionnaires written in English

Related Conditions & MeSH terms

• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic

Intervention

Device:
• Apollo Wearable
Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear everyday. They will be asked to continue to wear the device until all study data is collected.

Locations

Country	Name	City	State
United States	Apollo Neuroscience, Inc.	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Apollo Neuroscience, Inc.	The Board of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PTSD Checklist for DSM-5 (PCL-5)	PTSD Checklist for DSM-5 (PCL-5) will be used to measure symptoms of PTSD.	Through study completion, an average of two years
Primary	Beck Depression Inventory II (BDI-II)	Beck Depression Inventory II (BDI-II) will be used to measure symptoms of depression.	Through study completion, an average of two years
Secondary	World Health Organization Health and Work Performance Questionnaire (HPQ Short form)	World Health Organization Health and Work Performance Questionnaire (HPQ Short form) will be used to measure work performance.	Through study completion, an average of two years
Secondary	Alcohol Use Disorders Identification Test (AUDIT)	Alcohol Use Disorders Identification Test (AUDIT) will be used to measure alcohol use.	Through study completion, an average of two years
Secondary	Drug Use Disorders Identification Test (DUDIT)	Drug Use Disorders Identification Test (DUDIT) will be used to measure drug use	Through study completion, an average of two years
Secondary	Chronic Pain Grade Scale (CPGS)	Chronic Pain Grade Scale (CPGS) will be used to provide a measure of symptoms of pain. The CPGS is a multidimensional measure that assesses 2 dimensions of overall chronic pain severity: pain intensity and pain-related disability. The 3 subscale scores (characteristic pain intensity, disability score, and the disability points score) are used to classify subjects into 1 of the 5 pain severity grades: grade 0 for no pain, grade I for low disability-low intensity, grade II for low disability-high intensity, grade III for high disability-moderately limiting, and grade IV for high disability-severely limiting.	Through study completion, an average of two years

External Links

•   Participants who are interested in the study can use the screener link to verify their eligibility